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ABSTRACT
Diabetes is a major risk factor for atherosclerotic
cardiovascular disease (ASCVD) in which dys-
lipidaemia plays a crucial role. Statins are first
line therapy for primary and secondary pre-
vention of ASCVD; however, adverse events
include reversible musculoskeletal and liver side
effects in addition to a diabetogenic association.
In this short review, we provide a succinct nar-
rative of the future role and current trial data of
a novel first-in-class molecule, bempedoic acid.
The authors provide their expert insight with a
focus on Phase III randomised controlled trials
(RCT) of bempedoic acid. Bempedoic acid was
approved by the US Food and Drug Adminis-
tration (FDA) and the European Medicines
Agency (EMA) in February and March 2020,
respectively, and is a novel molecule which
inhibits cholesterol biosynthesis in the same
mechanistic pathway as statins. It is a first-in-
class small molecule, delivered as a prodrug and
administered as an oral, once-daily dose that
decreases low-density lipoprotein cholesterol
(LDL-C) levels. Phase II and III RCTs have
demonstrated efficacy with adequate safety data
as mono- or combination therapy with statins
and ezetimibe. Bempedoic acid is hepatically
converted to the active drug with a lack of
activation in skeletal muscle. Due to this novel
mechanism, musculoskeletal-related adverse
events exhibit a lower prevalence providing an
alternative pharmacotherapy in statin-intoler-
ant patients. Bempedoic acid may be used as an
adjunct to diet and maximally tolerated statin
therapy or in statin-intolerant patients for the
treatment of dyslipidaemia. The recent National
Institute of Health and Care Excellence (NICE)
(UK) technology appraisal guidance [TA694]
published in April 2021 recommended bempe-
doic acid with ezetimibe as a treatment option
for primary hypercholesterolaemia or mixed
dyslipidaemia if statins are not tolerated or
contraindicated and if there is inadequate con-
trol of LDL-C with ezetimibe alone. Addition-
ally, outcomes trials evaluating ‘hard’ endpoints
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in statin-intolerant patients or those with
ASCVD are currently underway.
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Key Summary Points
Diabetes is a major risk factor for
atherosclerotic cardiovascular disease
(ASCVD) and dyslipidaemia is a major
cause in establishing and/or worsening
ASCVD.
Statins are the mainstay drug therapy for
dyslipidaemia including in patients with
diabetes.
Many patients on statin therapy do not
receive the desired reduction in low-
density lipoprotein cholesterol (LDL-C)
particularly because of intolerance.
Bempedoic acid is a new lipid-lowering
drug which offers an alternative to statin
therapy.
The Cholesterol Lowering via Bempedoic
Acid, an ACL-Inhibiting Regimen (CLEAR)
trials have demonstrated efficacy in LDL-C
reduction with preliminary data
demonstrating no increase in new or
worsening of established diabetes.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.14510643.
INTRODUCTION
Atherosclerotic cardiovascular disease (ASCVD)
is a major cause of global mortality and dyslip-
idaemia is a key mechanism in establishing
ASCVD. Indeed, ASCVD remains the primary
cause of mortality and disability among patients
with diabetes mellitus. Data from the WHO
Multinational Study of Vascular Disease in
Diabetes (WHO MSVDD) study demonstrated
that cardiovascular disease was the most preva-
lent cause of death in type 1 diabetes mellitus
(44%) and type 2 diabetes mellitus (52%) [1]. A
number of studies confirmed the significance of
diabetes mellitus as an ASCVD risk factor and
demonstrated it as a similar risk equivalent
those with established ASCVD without diabetes
[2, 3].
There is an overwhelming amount of data in
support of low-density lipoprotein cholesterol
(LDL-C) as a risk factor for ASCVD. A number of
population-based studies have demonstrated
that optimal total cholesterol levels are about
150 mg/dl (3.8 mmol/l); this parallels an LDL-C
status of approximately 100 mg/dl (2.6 mmol/l)
[4, 5]. Indeed, statin therapy, which primarily
targets the LDL-C pathway, has a wealth of data
expanding over the last three decades demon-
strating its considerable efficacy in the preven-
tion of ASCVD and death [6, 7]. In addition,
ASCVD benefits from statin therapy are pri-
marily related to absolute LDL-C lowering [8].
Statins are recommended as first-line therapy in
both primary and secondary prevention cohorts
through the prevention of ASCVD [9] and are
one of the foundations of multi-risk factor
therapy in diabetes mellitus. Indeed, studies of
statins in diabetes demonstrate significant
reductions in both coronary and cerebrovascu-
lar events [10–12]. The American Diabetes
Association Standards of Medical Care in Dia-
betes (US) and the National Institute of Health
and Care Excellence (NICE) (UK) both advocate
a priority of lowering LDL-C primarily through
moderate intensity statin therapy [13–15].
For LDL-C lowering, statins are certainly the
drugs of choice due to the wealth of conclusive
evidence including hard cardiovascular out-
comes. However, regarding statin intolerance
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there has been a disparity about the true inci-
dence of side effects of statins and possible
harm from these side effects [16]. Randomised
controlled clinical trials report very low rates of
even the most well-authenticated side effects,
such as myopathy [17]. However, in uncon-
trolled observational studies muscle symptoms
are reported in as many as 10–20% of statin
recipients [18–24]. Current evidence also sug-
gests that statins are associated with a ‘diabeto-
genic’ potential by increasing the risk of new-
onset diabetes and worsening established dia-
betes through a modest increase in glycaemic
levels [25–27].
Previous reports outlined the risk of new-
onset diabetes in statin treatment which was
increased by 9% compared to those taking pla-
cebo, whilst intensive and cumulative statin
therapy was also associated with an increased
risk of diabetes development [26]. Although the
mechanism by which statins increase the inci-
dence of diabetes are not fully established, evi-
dence suggests a multi-factorial cause involving
the inhibition of b-cell glucose transporters,
delayed ATP production, pro-inflammatory and
oxidative b-cell effects of plasma-derived
cholesterol, inhibition of calcium channel-de-
pendent insulin secretion and b-cell apoptosis
[25].
The paradox is raised wherein statins, which
represent the strongest form of cardiovascular
risk reduction, may promote progression to
diabetes. However, the benefits of continued
statin therapy very much outweigh the poten-
tial diabetogenic risks, the introduction of
novel lipid-lowering agents may provide a pos-
sible solution for those at high risk of diabetes,
e.g. prediabetes/metabolic syndrome groups
with statin intolerance given its lack of delete-
rious effect on glycaemic control. Hence, there
is a current clinical need for an effective alter-
native to statin therapy for LDL-C-lowering.
This short review provides a succinct narra-
tive of the future role and current trial data of
the novel first-in-class molecule, bempedoic
acid, in the management of ASCVD and dys-
lipidaemia, with consideration of the excess of
ASCVD in diabetes mellitus.
METHODS
The authors provide their expert insight; in
addition, a literature search was undertaken on
bempedoic acid in PubMed, Google Scholar and
clinicaltrials.gov to ensure relevant trials were
discussed. The authors primarily focussed on
phase III randomised controlled trials (RCT) of
bempedoic acid. All seven available phase III
trials were reviewed, and four trials were chosen
based on completion with published and anal-
ysed results. This article is based on previously
conducted studies and does not contain novel
data of animal and human study origin.
RESULTS
Of seven phase III trials that evaluated bempe-
doic acid, four have been completed and pub-
lished: Cholesterol Lowering via Bempedoic
Acid, an ACL-Inhibiting Regimen (CLEAR) Har-
mony (NCT02666664), CLEAR Wisdom
(NCT02991118), CLEAR Tranquillity
(NCT03001076) and CLEAR Serenity
(NCT02988115). Table 1 outlines the primary
characteristics of these studies. Of the remaining
three trials, one is currently in process and two
have been completed but are yet to be published
and for the purpose of this review have not been
discussed [28]. All of the available trial data
demonstrate significant LDL-C reductions.
Phase III trials have demonstrated the effi-
cacy of bempedoic acid 180 mg once daily in
reducing LDL-C compared to placebo. The
CLEAR Harmony trial evaluated the efficacy and
safety of bempedoic acid 180 mg once daily
(n = 1488) versus placebo (n = 742) in patients
with ASCVD and/or heterozygous familial
hypercholesterolaemia (HeFH) receiving maxi-
mal dose of tolerated statins over 52 weeks [29].
At week 12, bempedoic acid reduced the mean
LDL-C level by 19.2 mg/dl (0.50 mmol/l) rep-
resenting 16.5% reduction from baseline
(P\0.001). Adverse event and serious adverse
event rates were similar in the bempedoic acid
group compared to the placebo group (78.5 vs.
78.7% and 14.5% vs. 14.0% respectively).
However, the incidence of adverse events lead-
ing to discontinuation was significantly higher
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in the bempedoic acid group (10.9%) than in
the placebo group (7.1%), as was the incidence
of gout (1.2% vs. 0.3% respectively). Similar
data with a significant reduction of LDL-C with
bempedoic acid 180 mg once daily compared to
placebo were reported in the CLEAR Wisdom
trial.
CLEAR Harmony and CLEAR Wisdom asses-
sed the safety and tolerability of 180 mg once
daily bempedoic acid versus placebo in patients
with high cardiovascular risk and elevated LDL
cholesterol not adequately controlled by their
current maximally tolerated statin therapy
[29, 30]. Both trials were of 52 weeks duration.
At 12 weeks bempedoic acid reduced the mean
placebo corrected LDL-C by -16.5% (CLEAR
Harmony) and -17.4% (CLEAR Wisdom) from
baseline [29, 30] and showed no greater risk of
adverse events compared to placebo CLEAR
(Harmony; 78.5% versus 78.7%, CLEAR Wis-
dom; 70.1% versus 70.8%) [29, 30]. CLEAR
Tranquillity observed the safety and efficacy of
bempedoic acid added to ezetimibe in statin-
intolerant patients with hypercholesterolaemia
[31]. In this 12-week trial, bempedoic acid
added to ezetimibe reduced LDL-C by 28.5%
more than placebo (p\0.001; - 23.5%
bempedoic acid, ? 5.0% placebo) [31]. The
efficacy and safety of bempedoic acid in
patients with statin intolerance were also stud-
ied in the CLEAR Serenity trial of 24 weeks
duration [32]. Patients with a history of intol-
erance two statins (one at the lowest available
dose) were randomised (2:1) to either 180 mg
once daily bempedoic acid or placebo once
daily [32]. At week 12 bempedoic acid treatment
significantly lowered LDL-C by a placebo cor-
rected - 21.4% (95% CI - 25.1 to - 17.7%;
p\0.001) [32].
Across all four trials bempedoic acid was well
tolerated [33]. Common adverse events inclu-
ded gout, urinary tract infections, nasopharyn-
gitis and hyperuricaemia [29–32]. In CLEAR
Harmony, the incidence of new-onset diabetes
or worsening diabetes was lower in the treat-
ment arm compared to placebo (n = 49 [3.3%]
vs. n = 40 [5.4%]) [29]. CLEAR wisdom found
that amongst patients with diabetes, HbA1c
decreased by 0.08% from baseline in the
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by 0.13% in the placebo cohort [30]. Favourable
glycaemic control included a reduction
in worsening was consistent over the 1-year
treatment period.
In CLEAR Tranquillity, 2.3% of patients in
the placebo arm developed diabetes compared
to 1.1% of patients in the intervention arm [31].
Similarly, new-onset or worsening diabetes was
less commonly seen in the bempedoic acid
treatment arm (2.1%) compared to placebo
(4.5%) in the CLEAR Serenity trial [32]. Fasting
glucose C 126 mg/dl and glycosylated hae-
moglobin C 6.5% (48 mmol/mol) was less fre-
quently observed in individuals in the
bempedoic acid cohort regardless of pre-exist-
ing diabetes compared to placebo [32].
A recent meta-analysis combined the out-
come of new-onset or worsening diabetes in
these four trials which reported 3.7% of indi-
viduals taking bempodic acid compared to 5.7%
of individuals on placebo [34]. Bempodeic acid
was associated with a risk reduction of 0.65
(95% CI 0.44–0.96; I2 = 23%) [34].
DISCUSSION
Bempedoic acid (NEXLETOL in the USA,
Nilemdo in the EU) (Diiachi Sankyo; Esperion)
(ETC-1002; ESP55016) is a first-in-class small
molecule, delivered as a prodrug and adminis-
tered as an oral, once-daily dose that decreases
LDL-C level. It was approved by both the US
Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) in February
and March 2020 respectively [35]. Bempedoic
acid is administered orally in one 180 mg dose
licensed by the FDA as an addition to maxi-
mally tolerated statin treatment in adults with
HeFH or established ASCVD who require addi-
tional lowering of LDL-C (US label). In the EU,
the licensed indication differs slightly and is
indicated in adults with primary hypercholes-
terolaemia (HeFH/non-familial) or mixed dys-
lipidaemia in combination with a statin with or
without other lipid-lowering therapies in peo-
ple unable to meet LDL-C targets with maximal
statin treatment alone or in combination with
other lipid-lowering therapies in people who are
statin intolerant or for whom a statin is
contraindicated (please see the British National
Formulary: https://bnf.nice.org.uk/drug/
bempedoic-acid.html).
Bempedoic acid is a prodrug. The activated
substance inhibits adenosine triphosphate
citrate lyase, which is involved in the choles-
terol biosynthesis in the liver upstream of b-
hydroxy b-methylglutaryl-CoA (HMG-CoA)
reductase, the enzyme that is antagonised by
statins. Similar to statins, bempedoic acid
depletes intracellular cholesterol leading to
upregulation of hepatic LDL receptor expres-
sion, thus increasing the clearance of circulat-
ing LDL-C. However, this is where the
similarities diverge and the activation through
primarily liver enzymes (very long-chain acyl-
CoA synthetase-1, which lacks expression in
skeletal muscle) is postulated to lessen the risk
of myopathy and musculoskeletal-related side
effects. Experimental and clinical data sug-
gest that bempedoic acid has anti-atheroscle-
rotic effects [36], improvement in glucose
homeaostasis [37], inflammation and blood
pressure [38] in addition to its LDL-C-lowering
activity [37]. Recently, a systematic review and
meta-analysis of seven clinical trials confirmed
its anti-inflammatory effect demonstrated by a
reduction in high-sensitivity c-reactive protein
(hsCRP) [mean difference compared to con-
trols: - 13.2%; 95% CI - 16.7% to - 9.79%;
P\ 0.001]. Given the accepted role of inflam-
mation and hsCRP as a surrogate biomarker of
systemic inflammation and the prediction of
ASCVD [39], these findings may be of prognos-
tic benefit, which needs to be further interro-
gated in in vivo mechanistic and post-marketing
studies. Bempedoic acid’s primary anti-
atherosclerotic benefit is through lowering LDL-
C; however, clearly its anti-inflammatory effect
may be also clinically relevant. Interestingly,
LDL-C reduction with evolocumab (a PCSK9
inhibitor) reduced absolute risk of ASCVD in
patients with higher baseline hsCRP [40]. Also,
in healthy persons without hyperlipidaemia
but with high hsCRP levels, LDL-C lowering
with rosuvastatin significantly reduced the
incidence of major ASCVD events [41].
Lipid-lowering therapy targeting the reduc-
tion of LDL-C reduces the risk of cardiovascular
disease and LDL-C also remains one of the best
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biomarkers for ASCVD. However, it should be
noted that the value of LDL-C as a surrogate
endpoint for ASCVD is not absolute given its
heterogeneous nature with differences in out-
comes in LDL-C-lowering drug effects [42]. For
instance, the use of fibrates as lipid-lowering
therapyhas demostrated no significant cardio-
vascular benefit [43]. Nonetheless, other drugs
such as bempedoic acid and ezetimibe have
shown favourable cardioprotective outcomes
[34, 43]. Given the undisputed causal relation-
ship between LDL-C and ASCVD [8] with no
known level below which further LDL-C lower-
ing ceases to be beneficial [44], the significant
LDL-C reduction with bempedoic acid provides
clear hope and the expectation that these data
will be translated into a reduction in ASCVD
events and subsequent mortality. Importantly,
the CLEAR Outcomes trial (NCT02993406) is
precisely evaluating hard ASCVD endpoints in
statin-intolerant patients or patients at high risk
of ASCVD and is currently underway; its future
results are eagerly awaited.
A number of phase III trials have shown the
efficacy of bempedoic acid 180 mg once daily in
reducing LDL-C compared to placebo. This
article has focussed on four phase III trials under
the CLEAR trials umbrella including Harmony,
Wisdom, Tranquillity and Serenity. Collectively
evidence from these trials has shown reductions
in LDL-C baseline of up to approximately 24%
after 12 weeks and was generally well tolerated
throughout the treatment length. Importantly,
the magnitude of LDL-C reduction in the
CLEAR Serenity trial is similar to that of low-
intensity statins (simvastatin 10 mg, lovastatin
20 mg, pravastatin 20 mg, fluvastatin 40 mg)
[6]. All of the aforementioned trials have
demonstrated an improvement in systemic
inflammation with a reduction in hsCRP and a
reduction in new onset or worsening of dia-
betes. In addition to the CLEAR Tranquillity
trial, another study has shown efficacy and
safety in combination with ezetimibe [45].
Based on these data a fixed dose combination of
bempedoic acid (180 mg) and ezetimibe (10 mg)
(NEXLIZET in the US, Nustendi in the EU)
has been released [35]. Despite no direct head-
to-head comparison with statins, the overall
musculoskeletal-related adverse events seem to
be lower providing an alternative pharma-
cotherapy in statin-intolerant patients [46].
A further recent meta-analysis demonstrated
a decreased risk of new-onset or worsening of
type 2 diabetes (odds ratio 0.59; 95% CI
0.39–0.90; P = 0.01) [33]. Clearly, this in con-
trast to statin therapy, which is associated with
an small increase in the absolute risk of new-
onset type 2 diabetes [47]. Although the cur-
rently published CLEAR series of trials had
reported improvement of hyperglycaemia and
reduction of worsening or new-onset diabetes,
most of the trials did not display a statistically
significant trend. Also, across these trials,
patients and events of interest were few. Indeed,
people with diabetes ranged between 20 and
30% of the full trial cohorts, however there was
no specific focus on prediabetic groups or
groups at high risk of progession to diabetes.
Further research in cohorts in metabolic syn-
drome or prediabetes with the specific intent to
delineate any putative beneficial anti-glycaemic
effect requires further study. Whilst bempedoic
acid has demonstrated promising outcomes, it
is important to note that statin therapy remains
the primary lipid-lowering therapy according to
international consensus [48–50].
Adherence to statins is a known challenge,
particularly amongst patients taking low-inten-
sity treatment. A large retrospective cohort
study reported adherence levels of 84% after 1
year of treatment in patients on high-intensity
treatment with CVD compared with adherence
of only 57% in patients on low-intensity treat-
ment [51]. After 6 years of therapy, adherence
rates in both groups dropped further to 72%
and 48% in the high- and low-intensity cohorts
respectively [51]. These results were supported
by a more recent study which retrospectively
observed patients from 2009 to 2016; overall,
approximately 53% of patients were adherent to
statin therapy [52]. Adherence and discontinu-
ation were related to intensity levels with
patients on high-intensity therapy being more
adherent (63.7%) and less likely to discontinue
treatment compared to those on moderate- or
low-intensity therapy [52].
The adherence to therapy is fundamental to
maximal possible reduction of cardiovascular
risk. Average risk reduction of cardiovascular
Diabetes Ther (2021) 12:1779–1789 1785
events is about 40% and 22% in patients
adhering to high- or low-intensity statin ther-
apy respectively [51]. This is compared to a risk
reduction of only 10% in high-intensity treat-
ment and 5% in low-intensity treatment in
patients with poor compliance [51].
Currently injectable therapy, e.g. PCSK9
inhibitors such as evolocumab, is an alternative
to statin therapy in patients with poor compli-
ance. It is given every 2 weeks and indicated in
patients with high cardiovascular risk and/or
primary HeFH and persistently raised LDL-C
[53]. However, its use is limited by cost [43]. The
issue of cardiovascular risk benefit in relation to
compliance poses the question of whether
adherence and thus cardiovascular risk would
be improved with newer and potentially, more
cost-effective therapy options such as bempe-
doic acid. However, a meta-analysis observed a
37% discontinuation rate of bempedoic acid
compared to placebo. There was no pattern that
could explain the increased risk of discontinu-
ation and thus this needs to be further investi-
gated [33].
CONCLUSIONS
Currently, many patients do not achieve the
desired reduction in LDL-C, particularly in sev-
ere hyperlipidaemias, in individuals who do not
tolerate the first-line statin therapy and even in
general diabetes cohorts [54]. Therefore, addi-
tion of bempedoic acid to the array of lipid-
lowering therapies is most welcome particularly
given the high prevalence of ASCVD in diabetes
mellitus. Indeed NICE technology appraisal
guidance [TA694] has recommended bempedoic
acid with ezetimibe as a treatment option for
primary hypercholesterolaemia or mixed dys-
lipidaemia if statins are not tolerated or con-
traindicated and if there is inadequate control
of LDL-C with ezetimibe alone. The approval of
the novel first-in-class drug, bempedoic acid,
has added to the armoury of lower LDL-C-low-
ering therapy available to physicians treating
dyslipidaemia and ASCVD.
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